Back to resultsStudy of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)
Primary Purpose
Psoriasis
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Risankizumab
Placebo for Risankizumab
Sponsored by
About this trial
This is an interventional treatment trial for Psoriasis focused on measuring Psoriasis, Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO), Risankizumab, SKYRIZI, ABBV-066
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of chronic palmoplantar plaque psoriasis (PPPsO) (with or without psoriatic arthritis) for at least 6 months before Baseline and a Palmoplantar Investigator's Global Assessment (ppIGA) of moderate or severe, at Screening and Baseline.
- Must have at Screening and Baseline a plaque psoriasis (PsO) body surface area (BSA) involvement of greater than or equal to one percent, an Static Physician's Global Assessment (sPGA) score of moderate to severe (greater than or equal to three), a PPASI moderate to severe (greater than or equal to eight), at least one additional PsO plaque outside of the palms and soles.
- Must be a candidate for systemic therapy as assessed by the investigator.
- Previously had inadequately controlled disease by topicals, phototherapy and/or systemic treatments.
Exclusion Criteria:
- History of PsO other than chronic plaque type PsO
- History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.
- Ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with PsO assessments.
- Evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV), Active tuberculosis, Active systemic infection/clinically important infections in the last two weeks prior to Baseline.
- Prior exposure to risankizumab.
Sites / Locations
- Advanced Research Associates - Glendale /ID# 219197
- Burke Pharmaceutical Research /ID# 223349
- NW Arkansas Clinical Trials Center /ID# 231602
- Dermatology Research Associates /ID# 219195
- Integrative Skin Science and Research /ID# 219216
- Medderm Associates /ID# 219210
- Colorado Center for Dermatology, PLLC /ID# 219223
- Skin Care Research - Hollywood /ID# 219184
- GSI Clinical Research, LLC /ID# 219175
- Savin Medical Group, LLC /ID# 227754
- Lenus Research & Medical Group /ID# 219202
- Hamilton Research, LLC /ID# 219224
- Arlington Dermatology /ID# 219211
- Northshore University Health System Dermatology Clinical Trials Unit /ID# 219220
- Dawes Fretzin, LLC /ID# 219219
- The Dermatology Center PSC - New Albany /ID# 219183
- Epiphany Dermatology of Kansas LLC /ID# 219208
- Allcutis Research LLC /ID# 222272
- David Fivenson, MD, PLC /ID# 219180
- Henry Ford Medical Center /ID# 219205
- Advanced Dermatology of the Midlands /ID# 219207
- Psoriasis Treatment Center of Central New Jersey /ID# 219201
- Forest Hills Dermatology Group /ID# 219200
- Icahn School of Medicine at Mount Sinai /ID# 219206
- ClinOhio Research Services /ID# 222298
- University of Pittsburgh MC /ID# 219203
- Velocity Clinical Research-Providence /ID# 223350
- Palmetto Clinical Trial Services /ID# 222275
- Palmetto Clinical Trial Services /ID# 222299
- International Clinical Research - Tennessee LLC /ID# 220930
- Menter Dermatology Res Inst /ID# 219161
- Center for Clinical Studies - Houston (Binz) /ID# 219221
- Advanced Clinical Research - Woseth Dermatology /ID# 224750
- Virginia Clinical Research, Inc. /ID# 219181
- Beacon Dermatology Inc /ID# 220940
- Dr. Chih-ho Hong Medical Inc. /ID# 220941
- Dr. Irina Turchin PC Inc. /ID# 220938
- NewLab Clinical Research Inc. /ID# 220934
- Dr. S.K. Siddha Medicine Professional Corporation /ID# 220936
- Research Toronto /ID# 220939
- Innovaderm Research Inc. /ID# 222126
- Centre de Recherche dermatologique du Quebec Metropolitain /ID# 220935
- Dr. Samuel Sanchez PSC /ID# 218789
- Cruz-Santana, Carolina, PR /ID# 218790
- Pan American Center for Oncology Trials, LLC /ID# 218788
- Clinical Research Puerto Rico /ID# 218787
- GCM Medical Group, PSC /ID# 218786
- Hospital Regional de Malaga /ID# 220900
- Hospital Universitario Basurto /ID# 220904
- Hospital Universitario de la Princesa /ID# 224911
- Hospital Universitario Ramon y Cajal /ID# 220908
- Hospital Universitario Virgen del Rocio /ID# 220907
- Hospital General Universitario de Valencia /ID# 220898
- Hospital Universitario y Politecnico La Fe /ID# 220903
- Hospital Clinico Universitario Lozano Blesa /ID# 222492
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Risankizumab
Placebo
Arm Description
Participants will receive risankizumab for 52 weeks
Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
Outcomes
Primary Outcome Measures
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
The ppIGA is a 5 point score ranging from 0 to 4, based on the investigator's assessment of the average erythema (redness), induration (thickness), and scaling of all palmoplantar (non-pustular) psoriatic lesions. A lower score indicates lower severity, with 0 being "clear" and 1 being "almost clear."
Number of Participants with Adverse Events
Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 20 weeks after last dose of study drug.
Secondary Outcome Measures
Percentage of Participants Achieving >= 75% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) response
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Percentage of Participants Achieving >= 90% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) response
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
sPGA is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Percentage of Participants Achieving 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) response
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04713592
Brief Title
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Acronym
IMMprint
Official Title
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects With Moderate to Severe Plaque Psoriasis With Palmoplantar (Non-Pustular) Involvement (PPPsO)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
February 26, 2021 (Actual)
Primary Completion Date
April 20, 2023 (Actual)
Study Completion Date
April 20, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AbbVie
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis with palmoplantar involvement and to assess change in disease symptoms.
Risankizumab is an approved drug for the treatment of psoriasis. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo in Period A. In Period B, all the participants will receive risankizumab. Around 168 adult participants with a moderate to severe plaque psoriasis will be enrolled in approximately 55 sites across the world.
Participants will receive single subcutaneous (administered under the skin) risankizumab or placebo in period A (16 weeks). In period B (36 weeks), all participants will receive subcutaneous risankizumab once every 12 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psoriasis
Keywords
Psoriasis, Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO), Risankizumab, SKYRIZI, ABBV-066
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
174 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Risankizumab
Arm Type
Experimental
Arm Description
Participants will receive risankizumab for 52 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
Intervention Type
Drug
Intervention Name(s)
Risankizumab
Other Intervention Name(s)
ABBV-066, SKYRIZI
Intervention Description
Subcutaneous (SC) Injection
Intervention Type
Drug
Intervention Name(s)
Placebo for Risankizumab
Intervention Description
Subcutaneous (SC) Injection
Primary Outcome Measure Information:
Title
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
Description
The ppIGA is a 5 point score ranging from 0 to 4, based on the investigator's assessment of the average erythema (redness), induration (thickness), and scaling of all palmoplantar (non-pustular) psoriatic lesions. A lower score indicates lower severity, with 0 being "clear" and 1 being "almost clear."
Time Frame
Baseline (Week 0) through Week 16
Title
Number of Participants with Adverse Events
Description
Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 20 weeks after last dose of study drug.
Time Frame
Baseline (Week 0) through 20 weeks after last dose of study drug (Up to 60 weeks total)
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving >= 75% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) response
Description
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Time Frame
Baseline (Week 0) through Week 16
Title
Percentage of Participants Achieving >= 90% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) response
Description
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Time Frame
Baseline (Week 0) through Week 16
Title
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
Description
sPGA is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Time Frame
Baseline (Week 0) through Week 16
Title
Percentage of Participants Achieving 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) response
Description
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
Time Frame
Baseline (Week 0) through Week 16
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic palmoplantar plaque psoriasis (PPPsO) (with or without psoriatic arthritis) for at least 6 months before Baseline and a Palmoplantar Investigator's Global Assessment (ppIGA) of moderate or severe, at Screening and Baseline.
Must have at Screening and Baseline a plaque psoriasis (PsO) body surface area (BSA) involvement of greater than or equal to one percent, an Static Physician's Global Assessment (sPGA) score of moderate to severe (greater than or equal to three), a PPASI moderate to severe (greater than or equal to eight), at least one additional PsO plaque outside of the palms and soles.
Must be a candidate for systemic therapy as assessed by the investigator.
Previously had inadequately controlled disease by topicals, phototherapy and/or systemic treatments.
Exclusion Criteria:
History of PsO other than chronic plaque type PsO
History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.
Ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with PsO assessments.
Evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV), Active tuberculosis, Active systemic infection/clinically important infections in the last two weeks prior to Baseline.
Prior exposure to risankizumab.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ABBVIE INC.
Organizational Affiliation
AbbVie
Official's Role
Study Director
Facility Information:
Facility Name
Advanced Research Associates - Glendale /ID# 219197
City
Glendale
State/Province
Arizona
ZIP/Postal Code
85308
Country
United States
Facility Name
Burke Pharmaceutical Research /ID# 223349
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71913-6404
Country
United States
Facility Name
NW Arkansas Clinical Trials Center /ID# 231602
City
Rogers
State/Province
Arkansas
ZIP/Postal Code
72758
Country
United States
Facility Name
Dermatology Research Associates /ID# 219195
City
Los Angeles
State/Province
California
ZIP/Postal Code
90045
Country
United States
Facility Name
Integrative Skin Science and Research /ID# 219216
City
Sacramento
State/Province
California
ZIP/Postal Code
95815
Country
United States
Facility Name
Medderm Associates /ID# 219210
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Colorado Center for Dermatology, PLLC /ID# 219223
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80111-1724
Country
United States
Facility Name
Skin Care Research - Hollywood /ID# 219184
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021-6748
Country
United States
Facility Name
GSI Clinical Research, LLC /ID# 219175
City
Margate
State/Province
Florida
ZIP/Postal Code
33063
Country
United States
Facility Name
Savin Medical Group, LLC /ID# 227754
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014-2490
Country
United States
Facility Name
Lenus Research & Medical Group /ID# 219202
City
Sweetwater
State/Province
Florida
ZIP/Postal Code
33172
Country
United States
Facility Name
Hamilton Research, LLC /ID# 219224
City
Alpharetta
State/Province
Georgia
ZIP/Postal Code
30022
Country
United States
Facility Name
Arlington Dermatology /ID# 219211
City
Rolling Meadows
State/Province
Illinois
ZIP/Postal Code
60008
Country
United States
Facility Name
Northshore University Health System Dermatology Clinical Trials Unit /ID# 219220
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60077
Country
United States
Facility Name
Dawes Fretzin, LLC /ID# 219219
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46256
Country
United States
Facility Name
The Dermatology Center PSC - New Albany /ID# 219183
City
New Albany
State/Province
Indiana
ZIP/Postal Code
47150
Country
United States
Facility Name
Epiphany Dermatology of Kansas LLC /ID# 219208
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66210
Country
United States
Facility Name
Allcutis Research LLC /ID# 222272
City
Methuen
State/Province
Massachusetts
ZIP/Postal Code
01844-5864
Country
United States
Facility Name
David Fivenson, MD, PLC /ID# 219180
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48103
Country
United States
Facility Name
Henry Ford Medical Center /ID# 219205
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202-3046
Country
United States
Facility Name
Advanced Dermatology of the Midlands /ID# 219207
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68144-1105
Country
United States
Facility Name
Psoriasis Treatment Center of Central New Jersey /ID# 219201
City
East Windsor
State/Province
New Jersey
ZIP/Postal Code
08520
Country
United States
Facility Name
Forest Hills Dermatology Group /ID# 219200
City
Kew Gardens
State/Province
New York
ZIP/Postal Code
11415
Country
United States
Facility Name
Icahn School of Medicine at Mount Sinai /ID# 219206
City
New York
State/Province
New York
ZIP/Postal Code
10029-6504
Country
United States
Facility Name
ClinOhio Research Services /ID# 222298
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43213-4440
Country
United States
Facility Name
University of Pittsburgh MC /ID# 219203
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15260
Country
United States
Facility Name
Velocity Clinical Research-Providence /ID# 223350
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886-1617
Country
United States
Facility Name
Palmetto Clinical Trial Services /ID# 222275
City
Fountain Inn
State/Province
South Carolina
ZIP/Postal Code
29644-1928
Country
United States
Facility Name
Palmetto Clinical Trial Services /ID# 222299
City
Fountain Inn
State/Province
South Carolina
ZIP/Postal Code
29644-1928
Country
United States
Facility Name
International Clinical Research - Tennessee LLC /ID# 220930
City
Murfreesboro
State/Province
Tennessee
ZIP/Postal Code
37130-2450
Country
United States
Facility Name
Menter Dermatology Res Inst /ID# 219161
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Center for Clinical Studies - Houston (Binz) /ID# 219221
City
Houston
State/Province
Texas
ZIP/Postal Code
77004-8097
Country
United States
Facility Name
Advanced Clinical Research - Woseth Dermatology /ID# 224750
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84117-4209
Country
United States
Facility Name
Virginia Clinical Research, Inc. /ID# 219181
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23507
Country
United States
Facility Name
Beacon Dermatology Inc /ID# 220940
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T3E 0B2
Country
Canada
Facility Name
Dr. Chih-ho Hong Medical Inc. /ID# 220941
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3R 6A7
Country
Canada
Facility Name
Dr. Irina Turchin PC Inc. /ID# 220938
City
Fredericton
State/Province
New Brunswick
ZIP/Postal Code
E3B 1G9
Country
Canada
Facility Name
NewLab Clinical Research Inc. /ID# 220934
City
St. John's
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1C 2H5
Country
Canada
Facility Name
Dr. S.K. Siddha Medicine Professional Corporation /ID# 220936
City
Newmarket
State/Province
Ontario
ZIP/Postal Code
L3Y 5G8
Country
Canada
Facility Name
Research Toronto /ID# 220939
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4W 2N4
Country
Canada
Facility Name
Innovaderm Research Inc. /ID# 222126
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 2V1
Country
Canada
Facility Name
Centre de Recherche dermatologique du Quebec Metropolitain /ID# 220935
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1V 4X7
Country
Canada
Facility Name
Dr. Samuel Sanchez PSC /ID# 218789
City
Caguas
ZIP/Postal Code
00727
Country
Puerto Rico
Facility Name
Cruz-Santana, Carolina, PR /ID# 218790
City
Carolina
ZIP/Postal Code
00985
Country
Puerto Rico
Facility Name
Pan American Center for Oncology Trials, LLC /ID# 218788
City
Rio Piedras
ZIP/Postal Code
00935
Country
Puerto Rico
Facility Name
Clinical Research Puerto Rico /ID# 218787
City
San Juan
ZIP/Postal Code
00909
Country
Puerto Rico
Facility Name
GCM Medical Group, PSC /ID# 218786
City
San Juan
ZIP/Postal Code
00909
Country
Puerto Rico
Facility Name
Hospital Regional de Malaga /ID# 220900
City
Málaga
State/Province
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Universitario Basurto /ID# 220904
City
Bilbao
State/Province
Vizcaya
ZIP/Postal Code
48013
Country
Spain
Facility Name
Hospital Universitario de la Princesa /ID# 224911
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Hospital Universitario Ramon y Cajal /ID# 220908
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocio /ID# 220907
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Hospital General Universitario de Valencia /ID# 220898
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Hospital Universitario y Politecnico La Fe /ID# 220903
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Hospital Clinico Universitario Lozano Blesa /ID# 222492
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD Sharing Time Frame
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD Sharing Access Criteria
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD Sharing URL
https://vivli.org/ourmember/abbvie/
Links:
URL
https://www.rxabbvie.com
Description
Related Info
Learn more about this trial
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
We'll reach out to this number within 24 hrs